Qianhai Health Holdings Ltd. (0911) AI Stock Analysis

• Market Cap: HK$39.14M
• Dividend Yield: N/A
• Average Volume (3M): 62.64K
• Price to Earnings (P/E): 30.0
• Beta (1Y): 0.82
• Revenue Growth: -45.94%
• EPS Growth: N/A
• Country: HK
• Employees: 14
• Sector: Healthcare
• Sector Strength: 40
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): <0.01
• Shares Outstanding: 169,445,000
• 10 Day Avg. Volume: 47,400
• 30 Day Avg. Volume: 62,641
• PEG Ratio: -0.32
• Price to Book (P/B): 0.11
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -2.45
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 53 Neutral
• Price Target: HK$0.00 ▼(-100.00%Downside)

The overall stock score of 53 reflects the combination of financial challenges, technical momentum, and high valuation. While the company shows some signs of financial improvement, cash flow issues and revenue inconsistencies present risks. The technical indicators suggest positive momentum, but the high P/E ratio and lack of dividends reduce the stock's attractiveness.

Qianhai Health Holdings Ltd. Business Overview & Revenue Model

Company Description

Qianhai Health Holdings Ltd. (0911) is a Hong Kong-based investment holding company primarily engaged in the health industry. The company operates through various segments, including health and wellness products, health management services, and the sale of healthcare-related products. It aims to leverage its expertise in health management to provide innovative and effective solutions to its customers.

How the Company Makes Money

Qianhai Health Holdings Ltd. generates revenue through the sale of health and wellness products, which may include nutritional supplements, personal care items, and other health-related goods. Additionally, the company offers health management services, which could encompass health assessments, consultancy, and personalized health plans. Revenue is also derived from strategic partnerships and collaborations that enhance its product offerings and expand its market reach. The company's earnings are influenced by its ability to effectively market its products and services, as well as its capacity to maintain and grow partnerships that provide access to broader consumer bases.

Qianhai Health Holdings Ltd. Financial Statement Overview

Summary

Qianhai Health Holdings Ltd. exhibits financial improvement with a return to profitability in 2024. However, significant revenue fluctuations and cash flow challenges pose potential risks. The balance sheet is strong with low debt levels, but addressing the cash flow issues is crucial for sustainable growth.

Income Statement

The company's revenue has shown significant volatility with a notable decline from 2022 to 2023. Despite this, the gross profit margin improved to 5.71% in 2024 from a negative margin in 2023. Net profit margins have improved from negative to a marginally positive 0.25% in 2024, indicating a turnaround. However, the negative revenue growth rate and fluctuating EBIT and EBITDA margins signal instability and potential risk.

Balance Sheet

The company maintains a strong equity position with an equity ratio of 94.67% in 2024, suggesting financial stability and low leverage risk with a debt-to-equity ratio of only 0.0027. However, the overall decrease in total assets over the years could be a concern for future growth potential.

Cash Flow

The cash flow situation is concerning, as operating and free cash flows were zero in 2024, indicating potential liquidity issues. The company has previously experienced negative cash flows, which could affect its ability to invest and grow.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	519.70M	961.29M	1.96B	283.40M	760.72M
Gross Profit	29.67M	-35.60M	76.48M	16.04M	45.13M
EBITDA	15.64M	-50.23M	-231.24M	2.06M	5.63M
Net Income	1.31M	-52.70M	-211.75M	1.48M	-6.41M
Balance Sheet
Total Assets	407.31M	478.12M	534.43M	738.63M	735.47M
Cash, Cash Equivalents and Short-Term Investments	23.51M	19.52M	1.64M	2.47M	16.36M
Total Debt	1.03M	487.00K	1.19M	7.83M	24.07M
Total Liabilities	21.74M	94.00M	97.73M	68.09M	62.28M
Stockholders Equity	385.57M	384.11M	436.70M	670.53M	673.19M
Cash Flow
Free Cash Flow	4.19M	857.00K	-5.26M	-44.19M	-70.90M
Operating Cash Flow	4.20M	857.00K	-5.26M	-44.18M	-70.89M
Investing Cash Flow	246.00K	17.77M	12.34M	46.84M	122.43M
Financing Cash Flow	-712.00K	-743.00K	-7.91M	-16.56M	-55.19M

Qianhai Health Holdings Ltd. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.23
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:0911, the sentiment is Negative. The current price of 0.23 is above the 20-day moving average (MA) of 0.23, above the 50-day MA of 0.21, and below the 200-day MA of 0.26, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 53.65 is Neutral, neither overbought nor oversold. The STOCH value of 83.20 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:0911.

Qianhai Health Holdings Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	60 Neutral	HK$15.31B	5.72	-7.43%	4.61%	11.60%	-21.06%
0911	53 Neutral	HK$39.14M	30.00	0.34%	―	-45.94%	―
8622	52 Neutral	HK$197.69M	―	-7.93%	―	1.13%	38.41%
0858	50 Neutral	HK$188.81M	0.86	23.02%	―	-12.93%	―
1652	49 Neutral	HK$286.74M	―	-40.39%	―	-43.73%	-434.56%
1498	47 Neutral	HK$197.47M	―	-26.80%	―	-6.09%	66.59%
1312	36 Underperform	HK$156.20M	―	-7.42%	―	10.93%	-159.62%

Qianhai Health Holdings Ltd. Corporate Events

Qianhai Health Holdings Ltd. Successfully Passes All AGM Resolutions

Qianhai Health Holdings Ltd. announced the successful passing of all resolutions at its Annual General Meeting held on June 25, 2025. The resolutions included the re-election of directors, approval of financial statements, and re-appointment of auditors, all of which received unanimous support from shareholders. This outcome reflects strong shareholder confidence and stability in the company’s governance, potentially enhancing its industry positioning and stakeholder trust.

Qianhai Health Holdings Enhances Nomination Committee with New Appointment

Qianhai Health Holdings Limited, a company incorporated in the Cayman Islands, has announced the appointment of Ms. Wu Hung Yu as a member of its Nomination Committee, effective from June 25, 2025. This appointment enhances the committee’s composition, which now includes Mr. Li Wei as chairman, alongside Mr. Yuen Chee Lap Carl, Mr. Leung Chun Tung, and Ms. Wu Hung Yu. The company extends a warm welcome to Ms. Wu Hung Yu, indicating a strategic move to strengthen its governance structure.

Qianhai Health Holdings Ltd. Announces Board Composition and Roles

Qianhai Health Holdings Ltd. announced the composition of its board of directors and their respective roles within the company. The board includes non-executive, executive, and independent non-executive directors, with specific members serving on the audit, remuneration, and nomination committees. This announcement provides clarity on the governance structure of the company, potentially impacting stakeholder confidence and operational transparency.

Qianhai Health Holdings Enhances Governance with Nomination Committee

Qianhai Health Holdings Limited has established a Nomination Committee as part of its Board of Directors, effective since June 9, 2014. The committee is tasked with selecting members from the company’s directors, ensuring diversity and independence, with at least one member of a different gender and a majority being independent non-executive directors. This move is likely to enhance the company’s governance structure and ensure a balanced representation in decision-making processes, potentially impacting its strategic direction and stakeholder confidence.

Qianhai Health Holdings Schedules Annual General Meeting for June 2025

Qianhai Health Holdings Limited has announced its upcoming Annual General Meeting (AGM) scheduled for June 25, 2025, in Hong Kong. The meeting will address several key resolutions, including the approval of the company’s audited financial statements for the year ending December 31, 2024, the re-election of four directors, and the reappointment of the company’s auditors. Shareholders will have the opportunity to vote on these resolutions and appoint proxies if necessary.